Communication in Action: Empowering Community Oncology Pharmacists to Optimize Prostate Cancer Care Across Urology and Oncology

Program Description

Prostate cancer continues to be the most common malignancy among men and a leading cause of cancer-related mortality, and it is estimated that more than 2 million new cancer cases will be diagnosed in the United States in 2026. Historically, treatment has relied on a backbone of androgen deprivation therapy, but the current treatment environment is increasingly defined by the challenge of balancing high-potency systemic therapies with the management of cumulative toxicities and resistance. Emerging strategies such as radiopharmaceutical therapies, next-generation PARP inhibitors, and new combinations for metastatic hormone-sensitive disease have significantly improved progression-free survival. These options have expanded the treatment landscape and offer the advantage of precision targeting while minimizing the off-target effects seen with traditional chemotherapy. Yet, these therapeutic advances necessitate robust and continuous education to ensure that community oncology pharmacists can navigate biomarker-driven selection, monitor for nuanced adverse effects like cognitive impact, and support patient adherence to oral regimens. Central to this program is a focus on structured communication strategies with urologists and medical oncologists, and this session will provide practical tools for standardized communication in shared care plans to ensure consistency in toxicity reporting and refill management.

Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 12, 2026
Expiration date: May 12, 2027
Learner level: Foundational, Intermediate
Time to complete activity: .75 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Apply current guideline recommendations and recently approved therapies for prostate cancer across disease stages for evidence-based treatment selection and sequencing in community oncology practice
• Investigate evolving clinical evidence and emerging therapies in prostate cancer to guide treatment sequencing and support evidence-based decision-making by community oncology pharmacists
• Adapt structured communication strategies with urologists and medical oncologists to ensure coordinated, guideline-concordant prostate cancer care in the community oncology setting